Imeik Technology Development (300896.SZ)

Overall impact
B (64)

Commentary

Imeik Technology is a strong overall performer. With a 'B' rating of 63.7 for overall impact (71st percentile compared to all companies), Imeik Technology ranks 59th out of 103 industry peers, behind Waters, MyMD Pharmaceuticals, Alphatec and 55 others, and ahead of Tandem Diabetes Care, InMode, Envista Holdings and 41 others. On top material causes for Imeik Technology's industry (Healthcare Equipment), Imeik Technology performs well in Technology Innovation (95.5 score) and Improved Mental Health (82.5) and performs poorly in Sanitation Access (39.3 score) and Child and Maternal Health (36.6).
Impact
Cause 300896.SZ
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Imeik Technology Development

Employees
1,458
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
China
Share classes
300896.SZ
Description
Imeik Technology Development Co.,Ltd. engages in the research and development, production, and transformation of biomedical soft tissue repair materials in China. The company offers aesthetic medicine products, including cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere, poly facial implant thread, medical sodium hyaluronate-hydroxypropyl methylcellulose gel, sodium hyaluronate composite solution for injection, modified sodium hyaluronate gel for injection, and medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel. It also provides skin care products. Imeik Technology Development Co.,Ltd. was incorporated in 2004 and is based in Beijing, China.
Material causes
Ethos considers the following causes material for Imeik Technology Development, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.